Health – Made in Germany goes Washington for 9th round of TTIP talks
Health – Made in Germany travelled to Washington in April for the ninth round of the Transatlantic Trade and Investment Partnership (TTIP) talks. The initiative followed the negotiations from April 20 to April 23 with a comprehensive program that included a roundtable discussion, a workshop and additional expert talks. These all presented comprehensive information about the planned accord between the European Union (EU) and the US.
German companies based in the US and a delegation from Germany made up of representatives from business and professional associations and companies took part in the events. They received in-depth information about the course of the negotiations and the current state of the TTIP talks. In addition, those who attended also engaged in discussions with American pharmaceuticals and medical technology companies about the effects of the planned accord and possible opportunities and risks for the health care industry.
Participants said the events successfully achieved their aim, which was comprehensive transfer of knowledge. A number of expert talks were also held with American decision-makers and key business figures including people from the U.S. Chamber of Commerce, American Chemistry Council (ACC), Consumer Health Products Association, Medical Imaging Technology Alliance (MITA), Pharmaceutical Research and Manufacturers of America (PhRMA) and the German Marshall Fund (GMF). It was possible during these discussions to raise US awareness of and sensitivity to German companies' perspectives. Background talks were also held with research institutions such as the Atlantic Council and the Bertelsmann Foundation.
The initiative Health – Made in Germany organized the event in cooperation with delegates from the Representative of German Industry and Trade (RGIT). RGIT is the liaison office for the Federation of German Industries (BDI) and the Association of German Chambers of Commerce and Industry in Washington.
TTIP is to reshape and streamline trade regulations for commerce between Europe and the US in the long-term. The ninth-round of talks on the accord was dedicated to cooperation on regulatory questions. Tariff reductions, services and public procurement were, for example, among the topics discussed. Reports say progress was achieved in the area of pharmaceuticals and medical products. Political responsibility and leadership of the talks rests with the European Commissions Directorate General for Trade for the EU and the Office of the United States Trade Representative (USTR) for the US.
If TTIP comes into force it is expected to have a major influence Germany's health care industry. Health – Made in Germany has been following the negotiations since they began last year. The initiative has also been hosting events regularly in Germany and the US to ensure business and regulators remain up-to-date on the status of the talks and the accord. It will follow the TTIP talks and continue to provide information until their conclusion. Health – Made in Germany is an initiative of Germany's Ministry for Economic Affairs and Energy (BMWi). Its aim is to show interested people from abroad the way to partners, investment opportunities, research and educational programs in Germany while assisting German health care companies in marketing their products abroad. The initiative's work is directed in part by four working groups composed of representatives of the pharmaceuticals, medical devices, medical biotechnology and telemedicine and health-related services sectors of the industry.